Skip to main content

Table 3 Patient distributions according to exon 19 deletion molecular subtype classifications

From: Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

  

All del19 patients (n = 26)

Number of nucleotide deletion

15-nucleotide deletion (15n-del)

21 (80.8%)

18-nucleotide deletion (18n-del)

1 (3.8%)

Other insertion/substitution (other/mixed ins/sub)

4 (15.4%)

Deletion starting codon

E746 group

20 (76.9%)

L747 group

5 (19.2%)

Non-LRE group

1 (3.8%)

LRE or non-LRE

LRE group

25 (96.2%)

non-LRE group

1 (3.8%)

ELREA or not

ELREA group

17 (65.4%)

non-ELREA group

9 (34.6%)